These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17137409)

  • 1. Tacrolimus: in heart transplant recipients.
    McCormack PL; Keating GM
    Drugs; 2006; 66(17):2269-79; discussion 2280-2. PubMed ID: 17137409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus: a further update of its use in the management of organ transplantation.
    Scott LJ; McKeage K; Keam SJ; Plosker GL
    Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppression management in renal transplant recipients with normal-immunological risk: 10-year results from the Swiss Transplant Cohort Study.
    Krisl A; Stampf S; Hauri D; Binet I; Mueller T; Sidler D; Hadaya K; Golshayan D; Pascual M; Koller M; Dickenmann M; The Swiss Transplant Cohort Study Stcs
    Swiss Med Wkly; 2020 Nov; 150():w20354. PubMed ID: 33277913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
    Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
    Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus in heart transplant recipients: an overview.
    Patel JK; Kobashigawa JA
    BioDrugs; 2007; 21(3):139-43. PubMed ID: 17516709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
    Herzberg GZ; Rossi AF; Courtney M; Gelb BD
    J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcineurin inhibitors in renal transplantation: what is the best option?
    Tanabe K
    Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus once-daily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients.
    Cross SA; Perry CM
    Drugs; 2007; 67(13):1931-43. PubMed ID: 17722962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus in transplant rejection.
    Rath T
    Expert Opin Pharmacother; 2013 Jan; 14(1):115-22. PubMed ID: 23228138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin inhibitors in pediatric renal transplant recipients.
    Filler G
    Paediatr Drugs; 2007; 9(3):165-74. PubMed ID: 17523697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
    Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
    Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation: 7-year observational results.
    Krämer BK; Montagnino G; Krüger B; Margreiter R; Olbricht CJ; Marcen R; Sester U; Kunzendorf U; Dietl KH; Rigotti P; Ronco C; Hörsch S; Banas B; Mühlbacher F; Arias M;
    Transpl Int; 2016 Mar; 29(3):307-14. PubMed ID: 26565071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of tacrolimus-based immunosuppression after heart or lung transplantation.
    Reichenspurner H
    J Heart Lung Transplant; 2005 Feb; 24(2):119-30. PubMed ID: 15701425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center.
    Kim HC; Hwang EA; Han SY; Park SB; Kim HT; Cho WH
    Transplant Proc; 2004 Sep; 36(7):2082-3. PubMed ID: 15518753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group.
    Mentzer RM; Jahania MS; Lasley RD
    Transplantation; 1998 Jan; 65(1):109-13. PubMed ID: 9448154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus based immunosuppression.
    First MR
    J Nephrol; 2004; 17 Suppl 8():S25-31. PubMed ID: 15599882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection.
    Viesselmann CW; Descourouez JL; Jorgenson MR; Radke NA; Odorico JS
    Pharmacotherapy; 2016 Mar; 36(3):335-41. PubMed ID: 26877191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.